Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12983419 | 0.98 | PTGS2 (0.50) | PTGS2PTGS1TRPV1NR3C2KLKB1 | |
| SCHEMBL287748 | 0.86 | PTGS2 (0.60) | PTGS2PTGS1TRPV1 | |
| SCHEMBL12981572 | 0.86 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL13172528 | 0.86 | TRPV1 (0.42) | PTGS2PTGS1TRPV1KLKB1 | |
| SCHEMBL13172610 | 0.85 | TRPV1 (0.46) | PTGS2PTGS1TRPV1KLKB1 | |
| Hydrochloric Acid SCHEMBL12982304 | 0.84 | TRPV1 (0.41) | PTGS2PTGS1TRPV1KLKB1 | |
| SCHEMBL12871665 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1TRPV1 | |
| Hydrochloric Acid SCHEMBL12982348 | 0.84 | TRPV1 (0.45) | PTGS2PTGS1TRPV1KLKB1 | |
| SCHEMBL14661976 | 0.84 | TRPV1 (0.51) | PTGS2TRPV1KLKB1 | |
| SCHEMBL287687 | 0.82 | TRPV1 (0.48) | PTGS2PTGS1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2776401-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068464-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-05-16 | — | — | WO | disclosed |
| EP-2427436-B1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2427436-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010127855-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | PTGS2 3299/4885PTGS1 3416/4885TRPV1 1/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | PTGS2 1336/4885PTGS1 1476/4885TRPV1 1/4885 |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, OPRM1, OPRK1 | PTGS2 855/4885PTGS1 397/4885TRPV1 1/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | PTGS2 1336/4885PTGS1 1476/4885TRPV1 1/4885 |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | PTGS2 1184/4885PTGS1 598/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.